Abbott Laboratories
Abbott Laboratories Reports Strong Fourth Quarter and Full Year 2024 Financial Results
Summary
On January 22, 2025, Abbott Laboratories announced its results of operations for the fourth quarter and full year 2024. Fourth-quarter sales increased 7.2 percent to $11.0 billion, while full-year 2024 sales reached $42.0 billion, up 4.6 percent. Organic sales growth, excluding COVID-19 testing-related sales, was 8.8 percent for the quarter and 9.6 percent for the year. Abbott also provided its 2025 financial outlook, projecting organic sales growth between 7.5% to 8.5%.
Profitelligence Alerts
Get alerts for ABT
Be first to know when Abbott Laboratories files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Abbott Laboratories
Abbott Laboratories, a globally renowned company, specializes in the development and production of healthcare and medical products. Founded in 1888 and headquartered in Abbott Park, Illinois, Abbott is a pivotal entity in the healthcare sector. The company provides essential products spanning diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals. Notably, Abbott's extensive diagnostic solutions include immunoassays and molecular diagnostics, crucial for medical testing and healthcare management. Its medical devices division produces cardiovascular and neuromodulation products, enhancing patient care across diverse medical practices. Abbott’s nutritional segment, featuring well-known brands like Similac and Ensure, supports health and wellness across various demographics. Serving markets globally, Abbott Laboratories plays a critical role in advancing healthcare infrastructure and delivering innovative solutions that address evolving health challenges worldwide. As a significant player in the life sciences field, Abbott's contributions significantly influence patient outcomes and healthcare delivery systems.
Official SEC Documents
Advertisement